News – Page 1079 – Endpoints News

Cellectis recruits ex-Servier research chief Depil; Arena inks $224M deal on new drugs; JLABS heads to Shanghai; ...

8 years ago

Analysts’ top 10 biotech takeover targets are concentrated in two key areas

8 years ago

Galectin PhIIb NASH trial fails the primary goal, but researchers hammer on the positive

8 years ago

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

8 years ago

Philippine health officials order Sanofi to halt Dengvaxia sales as controversy over health threat swells

8 years ago

Biopharma's top 10 overseas cash hoards. And what kind of M&A spree would $171B buy?

8 years ago

Michael Pellini has just joined Bill Maris at Section 32 — focused on patient care and drug development

8 years ago

Ra Pharma puts its best foot forward with PhII Soliris rival, but shares crash after comparison to Alexion’s ...

8 years ago

Venter quickly grabs the reins back at Human Longevity; Peter Thiel backs upstart ChemomAb

8 years ago

Stealthy Silverback recruits Seattle Genetics’ Eric Dobmeier as CEO, filling C-suite with oncology talent

8 years ago

CRISPR/Cas9 pioneer Chad Cowan enlists in Mustang Bio’s CAR-T quest

8 years ago

Atox Bio closes $30M round as it speeds through late-stage trials

8 years ago

Ultragenyx shares surge as blockbuster hopeful burosumab continues to perform in pivotal study

8 years ago

J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia

8 years ago

Sanofi’s belated admission of a lethal Dengvaxia threat came long after multiple high-profile warnings

8 years ago

Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure

8 years ago

Laura Shawver hits the ground running, scouting new investors for tiny Synthorx

8 years ago

Teva boots its R&D chief; Ironwood grows the C-suite and Intercept taps new EVP of research

8 years ago

Active Biotech shares crater after Teva's MS drug laquinimod flops (again); FDA approves Foundation Medicine's ...

8 years ago

Researchers use PD-1 checkpoint drug in pursuit of a promising curative approach to HIV

8 years ago

Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early

8 years ago

Astellas forges a $390M deal to buy a biotech focused on Ronald Evans’ ‘exercise-in-a-pill’ tech

8 years ago

Shire CEO Ornskov woos Bayer’s Andreas Busch to run Boston-based R&D group

8 years ago

What's killing patients in Bayer's Xofigo combo study? Researchers unblind study early to probe safety alert

8 years ago

First page Previous page 1076 1077 107810791080 1081 1082 Next page Last page